Journal
TUBERCULOSIS
Volume 96, Issue -, Pages 71-74Publisher
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.tube.2015.10.010
Keywords
MTBVAC; Newborn mice; Tuberculosis vaccine; Neonates
Categories
Funding
- Fundacion Espanola de la Ciencia y la Tecnologia [INC-098]
- Spanish Ministry of Economy and Competitiveness [BIO2011-23555, BIO2014-5258P]
- European Commission FP7 and H2020 programs [NEWTBVAC 241745, TBVAC2020 643381]
- Gobierno de Aragon/Fondo Social Europeo
Ask authors/readers for more resources
Development of novel more efficient preventive vaccines against tuberculosis (TB) is crucial to achieve TB eradication by 2050, one of the Millennium Development Goals (MDG) for the current century. MTBVAC is the first and only live attenuated vaccine based on a human isolate of Mycobacterium tuberculosis developed as BCG-replacement strategy in newborns that has entered first-in-human adult clinical trials. In this work, we characterize the safety, immunogenicity and protective efficacy of MTBVAC in a model of newborn C57/BL6 mice. Our data clearly indicate that MTBVAC is safe for newborn mice, and does not affect animal growth or organ development. In addition, MTBVAC-vaccinated mice at birth showed enhanced immunogenicity and better protection against M. tuberculosis challenge in comparison with BCG. (C) 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available